向日葵（维权）公告称，公司向上海兮噗科技有限公司支付了收购意向金人民币4000万元整。根据协议 约定，如本次交易终止，上海兮噗应在交易终止后5个工作日内将意向金退还。公司已向上海兮噗发送 《催收函》，要求其履行退款义务。双方同意共同探讨分期返还或其他可行的还款安排。 ...

人民财讯1月22日电，向日葵（维权）(300111)1月22日公告，公司于2025年9月10日召开会议审议通过 了《关于公司支付意向金的议案》。公司根据协议约定，向上海兮噗科技有限公司（简称"上海兮噗"） 支付了收购意向金4000万元。根据协议约定，如本次交易终止，上海兮噗应在交易终止后5个工作日内 将意向金退还。公司已于2026年1月15日向上海兮噗发送了《催收函》，要求其履行退款义务。经双方 友好协商，同意共同探讨分期返还或其他可行的还款安排。 转自：证券时报 ...

每经AI快讯，1月22日，向日葵（300111）(300111.SZ)公告称，公司已向上海兮噗发送《催收函》，要 求其履行退还4000万元收购意向金的义务。双方同意共同探讨分期返还或其他可行的还款安排。 ...

向日葵公告，公司于2025年9月10日召开董事会会议，审议通过了支付意向金的议案。根据协议约定， 公司向上海兮噗科技有限公司支付了收购意向金人民币肆仟万元整。随后，公司于2026年1月14日披露 了终止发行股份及支付现金购买资产并募集配套资金暨关联交易事项的公告。根据协议约定，上海兮噗 应在交易终止后5个工作日内将意向金退还。公司已于2026年1月15日向上海兮噗发送了《催收函》，要 求其履行退款义务。经双方友好协商，同意共同探讨分期返还或其他可行的还款安排。后续公司将根据 相关法律法规的规定履行信息披露义务。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）于 2025 年 9 月 10 日召开第六届董事会第八次会议，审议通过了《关于公司支付意向金的议案》， 具体内容详见当日公司在巨潮资讯网（www.cninfo.com.cn）披露的《第六届董事 会第八次会议决议公告》（公告编号：2025-035）。公司根据协议约定，向上海兮 噗科技有限公司（以下简称"上海兮噗"）支付了收购意向金人民币肆仟万元整。 公司于 2026 年 1 月 14 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于 终止发行股份及支付现金购买资产并募集配套资金暨关联交易事项的公告》（公 告编号：2026-002）。根据协议约定：如本次交易终止，上海兮噗应在交易终止 后 5 个工作日内将意向金退还。公司已于 2026 年 1 月 15 日向上海兮噗发送了《催 收函》，要求其履行退款义务。经双方友好协商，同意共同探讨分期返还或其他 可行的还款安排。后续公司将根据相关法律法规的规定履行信息披露义务。 特此公告。 浙江向日葵大健康科技股份 ...

Market Overview - The chemical pharmaceutical sector experienced a slight decline of 0.05% on January 21, with Sunflower leading the drop [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Performers - The following companies showed significant gains: - Aoheng Pharmaceutical (002437) closed at 3.51, up 10.03% with a trading volume of 1.9852 million shares and a transaction value of 693 million yuan [1] - Guobang Pharmaceutical (605507) closed at 26.96, up 6.81% with a trading volume of 132,600 shares and a transaction value of 357 million yuan [1] - Laimei Pharmaceutical (300006) closed at 5.24, up 6.50% with a trading volume of 670,800 shares and a transaction value of 345 million yuan [1] Underperformers - The following companies faced notable declines: - Sunflower (300111) closed at 4.64, down 6.07% with a trading volume of 1.514 million shares and a transaction value of 708 million yuan [2] - Hanshang Group (600774) closed at 10.94, down 6.01% with a trading volume of 436,600 shares and a transaction value of 470 million yuan [2] - Huabang Health (002004) closed at 5.40, down 4.42% with a trading volume of 1.1395 million shares and a transaction value of 618 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 239 million yuan from institutional investors, while retail investors contributed a net inflow of 58.25 million yuan [2] - However, there was a net outflow of 297 million yuan from speculative funds [2] Individual Stock Capital Flow - Aoheng Pharmaceutical (002437) had a net inflow of 206 million yuan from institutional investors, accounting for 29.69% of its total trading [3] - Tonghua Golden Horse (000766) saw a net inflow of 74.79 million yuan from institutional investors, representing 14.69% [3] - Fuxing Pharmaceutical (600196) experienced a net inflow of 64.35 million yuan from institutional investors, making up 14.11% [3]

Group 1 - The core viewpoint of the articles emphasizes the regulatory body's strict stance against information disclosure violations, signaling a "zero tolerance" approach to misleading statements in the capital market [1][2][3] - The China Securities Regulatory Commission (CSRC) has initiated investigations into three companies for suspected violations of information disclosure laws, highlighting the importance of accurate and complete information for investor decision-making [1][2] - The investigations into Ningbo Rongbai New Energy Technology Co., Ltd., Ningbo Tianpu Rubber Technology Co., Ltd., and Zhejiang Sunflower Health Technology Co., Ltd. reveal issues such as significant omissions and misleading statements that disrupt market order and infringe on investors' rights [1][2] Group 2 - The potential for insider trading and market manipulation exists behind significant omissions and misleading statements, which can distort market pricing and lead to substantial investor losses [2] - The CSRC's actions are crucial for maintaining market order and provide a basis for potential civil compensation and criminal accountability for investors who suffer losses [2] - The articles stress the need for public companies to enhance compliance awareness and governance to prevent information disclosure violations and promote long-term value growth [2][3] Group 3 - The recent regulatory actions serve as a warning to the market and are essential for the long-term healthy development of the capital market [3] - A commitment to integrity and compliance is necessary for the high-quality development of the capital market, as reiterated by the CSRC Chairman [2][3]

Core Viewpoint - Recent developments indicate that Zhejiang Sunflower (code: 300111) is under investigation for alleged securities misrepresentation, with affected investors preparing to file lawsuits [1][2][3]. Group 1: Company Investigation - The China Securities Regulatory Commission (CSRC) announced on January 14, 2026, that Zhejiang Sunflower's restructuring plan, disclosed on September 22, 2025, has raised market concerns regarding its actual production capacity and business model [1][3]. - The Zhejiang Securities Regulatory Bureau has initiated an investigation into the alleged misleading statements in the restructuring proposal, aiming to maintain order in the mergers and acquisitions market [1][4]. Group 2: Legal Proceedings and Investor Rights - According to the Supreme People's Court's judicial interpretation on false statements, investors whose rights have been harmed by such actions can file lawsuits for compensation, including losses from price differences, commissions, and stamp duty [2][4]. - Investors who purchased Zhejiang Sunflower shares between September 22, 2025, and December 25, 2025, and still held them at the close on December 25, 2025, are eligible to seek compensation, with conditions subject to adjustment based on the CSRC's investigation findings [2][4]. - Required documentation for investors seeking compensation includes securities account information, stock reconciliation statements from September 1, 2025, to the present, and contact information [2][4].

Core Viewpoint - The stock "向日葵" (Sunflower) experienced a significant increase, reaching a daily limit up of 20.00%, with a trading volume of 1.13 billion yuan and a turnover rate of 19.63% [2] Group 1: Trading Activity - The stock's trading data showed a total turnover of 1.13 billion yuan, with a price fluctuation of 22.31% throughout the day [2] - Institutional investors net bought 25.43 million yuan, while the Shenzhen Stock Connect recorded a net purchase of 27.70 million yuan [2] - The top five trading departments accounted for a total transaction of 230 million yuan, with a net buying amount of 41.36 million yuan [2] Group 2: Institutional Participation - Three institutional special seats were involved in the trading, with a total net purchase of 25.43 million yuan from these seats [2] - The Shenzhen Stock Connect was the largest buying and selling department, with a buying amount of 67.82 million yuan and a selling amount of 40.13 million yuan [2] Group 3: Historical Performance - Over the past six months, the stock has appeared on the trading list eight times, with an average price increase of 4.45% the day after being listed and an average increase of 0.32% over the following five days [3] - The stock saw a net inflow of 56.05 million yuan from major funds today, with a significant inflow of 94.67 million yuan from large orders [3]

Group 1 - The company Sunflower (300111) has received a notice from the China Securities Regulatory Commission (CSRC) regarding a formal investigation due to suspected violations of information disclosure laws [2] - Investors who purchased the stock between September 22, 2025, and December 25, 2025, and held it after the market closed on December 25, 2025, are eligible to apply for compensation for their losses [2] Group 2 - The company announced the termination of its plan to acquire 100% equity of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% equity of Zhejiang Beid Pharmaceutical Co., Ltd. through a share issuance and cash payment [4] - The CSRC's inquiry highlighted that Xipu Materials, based in Fujian Zhangzhou, has no actual production capacity at its factories in Zhangzhou and Lanzhou, despite being a core supplier for several wafer fabs [4] - The inquiry also requested detailed information on Xipu Materials' production capacity, including the status of approvals, construction, and production at its factories [4] Group 3 - Xipu Materials is primarily engaged in the research, manufacturing, and sales of high-end semiconductor materials, with core products including high-purity electronic gases and silicon-based precursors [5] - The inquiry requested financial details regarding Xipu Materials' revenue, costs, and gross margins for 2023 and 2024, as well as information on its transactions with Shanghai Deen Hong New Materials Technology Co., Ltd. [5] - Concerns were raised about potential adverse impacts on competition and independence due to the restructuring, as well as the legal issues faced by Xipu Materials' actual controller, which could affect asset transfers [5]